Ulrike Leiter
Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single institutional cohort study.
Wagner N, Knierim S, Luttermann F, Metzler G, Yazdi A, Bauer J, Gassenmaier M, Forschner A, Leiter U, Amaral T, Garbe C, Eigentler T, Forchhammer S, Flatz L. Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single institutional cohort study. J Am Acad Dermatol 2023
01.12.2023Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single institutional cohort study.
01.12.2023J Am Acad Dermatol 2023
Wagner Nikolaus, Knierim Sarah M, Luttermann Felix, Metzler Gisela, Yazdi Amir Sadegh, Bauer Jürgen, Gassenmaier Maximilian, Forschner Andrea, Leiter Ulrike, Amaral Teresa, Garbe Claus, Eigentler Thomas Kurt, Forchhammer Stephan, Flatz Lukas
Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma.
Nübel C, Amaral T, Leiter U, Flatz L, Forschner A. Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma. Front Oncol 2023; 13:1256800.
30.11.2023Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma.
30.11.2023Front Oncol 2023; 13:1256800
Nübel Charlotte, Amaral Teresa, Leiter Ulrike, Flatz Lukas, Forschner Andrea
Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Wagner N, Lenders M, Kühl K, Reinhardt L, Fuchß M, Ring N, Stäger R, Zellweger C, Ebel C, Kimeswenger S, Oellinger A, Amaral T, Forschner A, Leiter U, Klumpp B, Hoetzenecker W, Terheyden P, Mangana J, Loquai C, Cozzio A, Garbe C, Meier F, Eigentler T, Flatz L. Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy. Eur J Cancer 2023; 196:113425.
21.11.2023Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
21.11.2023Eur J Cancer 2023; 196:113425
Wagner Nikolaus, Lenders Max M, Kühl Kathrin, Reinhardt Lydia, Fuchß Milena, Ring Natalie, Stäger Ramon, Zellweger Caroline, Ebel Chiara, Kimeswenger Susanne, Oellinger Angela, Amaral Teresa, Forschner Andrea, Leiter Ulrike, Klumpp Bernhard, Hoetzenecker Wolfram, Terheyden Patrick, Mangana Joanna, Loquai Carmen, Cozzio Antonio, Garbe Claus, Meier Friedegund, Eigentler Thomas Kurt, Flatz Lukas
[Die Prognose des Melanoms im Kopf-Hals-Bereich im Stadium II hängt vom histologischen Subtyp ab].
Jasper S, Keim U, Leiter U, Amaral T, Flatz L, Forschner A. [Die Prognose des Melanoms im Kopf-Hals-Bereich im Stadium II hängt vom histologischen Subtyp ab]. J Dtsch Dermatol Ges 2023; 21:1137-1147.
01.10.2023[Die Prognose des Melanoms im Kopf-Hals-Bereich im Stadium II hängt vom histologischen Subtyp ab].
01.10.2023J Dtsch Dermatol Ges 2023; 21:1137-1147
Jasper Sophie, Keim Ulrike, Leiter Ulrike, Amaral Teresa, Flatz Lukas, Forschner Andrea
Prognosis in stage II melanoma of the head and neck depends on the histological subtype.
Jasper S, Keim U, Leiter U, Amaral T, Flatz L, Forschner A. Prognosis in stage II melanoma of the head and neck depends on the histological subtype. J Dtsch Dermatol Ges 2023; 21:1137-1146.
23.07.2023Prognosis in stage II melanoma of the head and neck depends on the histological subtype.
23.07.2023J Dtsch Dermatol Ges 2023; 21:1137-1146
Jasper Sophie, Keim Ulrike, Leiter Ulrike, Amaral Teresa, Flatz Lukas, Forschner Andrea
EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy.
Amaral T, Pop O, Chatziioannou E, Sinnberg T, Niessner H, Zhao J, Ring S, Jörger M, Schroeder C, Armeanu-Ebinger S, Cozzio A, Leiter U, Thomas I, Jochum W, Garbe C, Forchhammer S, Levesque M, Mangana J, Hölzel M, Dummer R, Schürch C, Forschner A, Flatz L. EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy. J Am Acad Dermatol 2023; 89:1072-1074.
22.07.2023EGFR expression is associated with relapse in a melanoma cohort receiving adjuvant PD-1-based immunotherapy.
22.07.2023J Am Acad Dermatol 2023; 89:1072-1074
Amaral Teresa, Pop Oltin Tiberiu, Chatziioannou Eftychia, Sinnberg Tobias, Niessner Heike, Zhao Jing Hua, Ring Sandra Stephanie, Jörger Markus, Schroeder Christopher, Armeanu-Ebinger Sorin, Cozzio Antonio, Leiter Ulrike, Thomas Ioannis, Jochum Wolfram, Garbe Claus, Forchhammer Stephan, Levesque Mitchell Paul, Mangana Joanna, Hölzel Michael, Dummer Reinhard, Schürch Christian M, Forschner Andrea, Flatz Lukas
Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.
Chatziioannou E, Leiter U, Thomas I, Keim U, Seeber O, Meiwes A, Boessenecker I, Gonzalez S, Torres F, Niessner H, Sinnberg T, Forschner A, Flatz L, Amaral T. Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy. Am J Clin Dermatol 2023; 24:453-467.
04.05.2023Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy.
04.05.2023Am J Clin Dermatol 2023; 24:453-467
Chatziioannou Eftychia, Leiter Ulrike, Thomas Ioannis, Keim Ulrike, Seeber Olivia, Meiwes Andreas, Boessenecker Isabell, Gonzalez Stephanie Sanchez, Torres Francisco Merraz, Niessner Heike, Sinnberg Tobias, Forschner Andrea, Flatz Lukas, Amaral Teresa
Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
Amaral T, Sinnberg T, Chatziioannou E, Niessner H, Leiter U, Keim U, Forschner A, Dwarkasing J, Tjien-Fooh F, Wever R, Flatz L, Eggermont A, Forchhammer S. Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP). Eur J Cancer 2022; 182:155-162.
30.12.2022Identification of stage I/II melanoma patients at high risk for recurrence using a model combining clinicopathologic factors with gene expression profiling (CP-GEP).
30.12.2022Eur J Cancer 2022; 182:155-162
Amaral Teresa, Sinnberg Tobias, Chatziioannou Eftychia, Niessner Heike, Leiter Ulrike, Keim Ulrike, Forschner Andrea, Dwarkasing Jvalini, Tjien-Fooh Félicia, Wever Renske, Flatz Lukas, Eggermont Alexander, Forchhammer Stephan
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
Garbe C, Keim U, Amaral T, Berking C, Eigentler T, Flatz L, Gesierich A, Leiter U, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zimmer L, Zouboulis C, Ascierto P, Eggermont A, Grob J, Hauschild A, Sekulovic L, Long G, Luke J, Michielin O, Peris K, Schadendorf D, Kirkwood J, Lorigan P, Central Malignant Melanoma Registry (CMMR). Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. J Clin Oncol 2022; 40:3741-3749.
16.06.2022Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
16.06.2022J Clin Oncol 2022; 40:3741-3749
Garbe Claus, Keim Ulrike, Amaral Teresa, Berking Carola, Eigentler Thomas Kurt, Flatz Lukas, Gesierich Anja, Leiter Ulrike, Stadler Rudolf, Sunderkötter Cord, Tüting Thomas, Utikal Jochen, Wollina Uwe, Zimmer Lisa, Zouboulis Christos C, Ascierto Paolo Antonio, Eggermont Alexander M M, Grob Jean-Jacques, Hauschild Axel, Sekulovic Lidija Kandolf, Long Georgina V, Luke Jason J, Michielin Olivier, Peris Ketty, Schadendorf Dirk, Kirkwood John M, Lorigan Paul C, Central Malignant Melanoma Registry (CMMR)
Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry
Serna-Higuita L, Eigentler T, Garbe C, Thomas I, Seeber O, Flatz L, Leiter U, Forschner A, Amaral T, Martus P. Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. Cancers (Basel) 2021; 13
06.12.2021Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry
06.12.2021Cancers (Basel) 2021; 13
Serna-Higuita Lina María, Eigentler Thomas Kurt, Garbe Claus, Thomas Ioannis, Seeber Olivia, Flatz Lukas, Leiter Ulrike, Forschner Andrea, Amaral Teresa, Martus Peter
Cutaneous melanoma attributable to UVR exposure in Denmark and Germany
Keim U, Gandini S, Amaral T, Katalinic A, Holleczek B, Flatz L, Leiter U, Whiteman D, Garbe C. Cutaneous melanoma attributable to UVR exposure in Denmark and Germany. Eur J Cancer 2021; 159:98-104.
03.11.2021Cutaneous melanoma attributable to UVR exposure in Denmark and Germany
03.11.2021Eur J Cancer 2021; 159:98-104
Keim Ulrike, Gandini Sara, Amaral Teresa, Katalinic Alexander, Holleczek Bernd, Flatz Lukas, Leiter Ulrike, Whiteman David, Garbe Claus
Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036
Garbe C, Leiter U, Flatz L, Martus P, Hollezcek B, Katalinic A, Amaral T, Gandini S, Keim U, Whiteman D. Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036. Eur J Cancer 2021; 152:18-25.
29.05.2021Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036
29.05.2021Eur J Cancer 2021; 152:18-25
Garbe Claus, Leiter Ulrike, Flatz Lukas, Martus Peter, Hollezcek Bernd, Katalinic Alexander, Amaral Teresa, Gandini Sara, Keim Ulrike, Whiteman David
Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
Gassenmaier M, Lenders M, Forschner A, Leiter U, Weide B, Garbe C, Eigentler T, Wagner N. Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors. Target Oncol 2021; 16:197-205.
08.02.2021Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
08.02.2021Target Oncol 2021; 16:197-205
Gassenmaier Maximilian, Lenders Max M, Forschner Andrea, Leiter Ulrike, Weide Benjamin, Garbe Claus, Eigentler Thomas K, Wagner Nikolaus
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study
Wagner N, Schraag A, Klumpp B, Hoetzenecker W, Berking C, Richtig E, Ziemer M, Mangana J, Terheyden P, Loquai C, Nguyen V, Gebhardt C, Meier F, Diem S, Cozzio A, Flatz L, Röcken M, Garbe C, Gassenmaier M, Weide B, Leiter U, Lenders M, Kühl K, Reinhardt L, André F, Dudda M, Ring N, Ebel C, Stäger R, Zellweger C, Lang R, Paar M, Gussek P, Richtig G, Stürmer S, Kimeswenger S, Oellinger A, Forschner A, Eigentler T. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. J Immunother Cancer 2021; 9
01.01.2021Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study
01.01.2021J Immunother Cancer 2021; 9
Wagner Nikolaus, Schraag Amadeus, Klumpp Bernhard, Hoetzenecker Wolfram, Berking Carola, Richtig Erika, Ziemer Mirjana, Mangana Johanna, Terheyden Patrick, Loquai Carmen, Nguyen Van Anh, Gebhardt Christoffer, Meier Friedegund, Diem Stefan, Cozzio Antonio, Flatz Lukas, Röcken Martin, Garbe Claus, Gassenmaier Maximilian, Weide Benjamin, Leiter Ulrike, Lenders Max M, Kühl Kathrin, Reinhardt Lydia, André Fiona, Dudda Milena, Ring Natalie, Ebel Chiara, Stäger Ramon, Zellweger Caroline, Lang Roland, Paar Michael, Gussek Philipp, Richtig Georg, Stürmer Suzan H, Kimeswenger Susanne, Oellinger Angela, Forschner Andrea, Eigentler Thomas K
Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors
Winter J, Eigentler T, Garbe C, Röcken M, Cozzio A, Flatz L, Purde M, Weide B, Leiter U, Forschner A, Gassenmaier M, Lenders M, Wagner N. Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors. Cancer Immunol Immunother 2020; 70:1089-1099.
28.10.2020Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors
28.10.2020Cancer Immunol Immunother 2020; 70:1089-1099
Winter Johanna, Eigentler Thomas K, Garbe Claus, Röcken Martin, Cozzio Antonio, Flatz Lukas, Purde Mette-Triin, Weide Benjamin, Leiter Ulrike, Forschner Andrea, Gassenmaier Maximilian, Lenders Max M, Wagner Nikolaus
Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy
Wagner N, Luttermann F, Gassenmaier M, Forschner A, Leiter U, Garbe C, Eigentler T. Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy. Australas J Dermatol 2020; 61:e310-e318.
12.02.2020Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy
12.02.2020Australas J Dermatol 2020; 61:e310-e318
Wagner Nikolaus, Luttermann Felix, Gassenmaier Maximilian, Forschner Andrea, Leiter Ulrike, Garbe Claus, Eigentler Thomas K
S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
Wagner N, Forschner A, Leiter U, Garbe C, Eigentler T. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. Br J Cancer 2018; 119:339-346.
28.06.2018S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
28.06.2018Br J Cancer 2018; 119:339-346
Wagner Nikolaus, Forschner Andrea, Leiter Ulrike, Garbe Claus, Eigentler Thomas K
Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients
Meier F, Garbe C, Knaudt B, Zielinski C, Leiter U, Forschner A, Eigentler T, Clasen S, Guenova E, Berneburg M. Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients. J Am Acad Dermatol 2009; 60:863-8.
01.05.2009Significant response after treatment with the mTOR inhibitor sirolimus in combination with carboplatin and paclitaxel in metastatic melanoma patients
01.05.2009J Am Acad Dermatol 2009; 60:863-8
Meier Friedegund, Garbe Claus, Knaudt Björn, Zielinski Christina, Leiter Ulrike, Forschner Andrea, Eigentler Thomas, Clasen Stephan, Guenova Emmanuella, Berneburg Mark